VORICONAZOLE-INDUCED HEPATOTOXICITY CONCISE UP-TO-DATE REVIEW
JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES, cilt.6, sa.1, ss.325-334, 2022 (ESCI, TRDizin)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 6 Sayı: 1
- Basım Tarihi: 2022
- Doi Numarası: 10.30621/jbachs.1051669
- Dergi Adı: JOURNAL OF BASIC AND CLINICAL HEALTH SCIENCES
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.325-334
- Anahtar Kelimeler: Voriconazole, Hepatotoxicity, Drug induced liver injury, plasma voriconazole concentration, CYP2C19 genotype
- Dokuz Eylül Üniversitesi Adresli: Evet
Özet
Voriconazole is a wide spectrum antifungal used primarily for invasive aspergillosis, an invasive mold infection occurs mostly in immunocompromised patients. Hepatotoxicity is the most common voriconazole-related adverse reaction that leads to treatment discontinuation. Even though reported incidence of hepatic adverse reactions during phase 2 and 3 clinical trials were less than 10%, observational studies in post marketing phase revealed much higher incidence reaching up to 69%. Therefore, the burden caused by hepatotoxicity and interruption of antifungal therapy put immunocompromised patients at serious risk.